Barclays PLC Revolution Medicines, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Barclays PLC holds 294,664 shares of RVMD stock, worth $16.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

294,664

Previous 294,664 -0.0%

Holding current value

$16.6 Million

Previous $13.4 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$36.92 - $47.94 $7.09 Million - $9.21 Million	192,021 Added 187.08%	294,664 $13.4 Million
Q2 2024 Aug 14, 2024	SELL	$30.14 - $40.68 $987,778 - $1.33 Million	-32,773 Reduced 24.2%	102,643 $3.98 Million
Q1 2024 May 15, 2024	SELL	$26.56 - $33.55 $5.8 Million - $7.33 Million	-218,369 Reduced 61.72%	135,416 $4.36 Million
Q4 2023 Feb 15, 2024	BUY	$18.35 - $34.12 $2.3 Million - $4.27 Million	125,124 Added 54.72%	353,785 $10.1 Million
Q3 2023 Nov 07, 2023	BUY	$25.17 - $35.05 $1.07 Million - $1.48 Million	42,336 Added 22.72%	228,661 $6.33 Million
Q2 2023 Aug 03, 2023	BUY	$20.28 - $27.0 $778,265 - $1.04 Million	38,376 Added 25.94%	186,325 $4.98 Million
Q1 2023 May 04, 2023	BUY	$20.76 - $30.09 $123,522 - $179,035	5,950 Added 4.19%	147,949 $3.21 Million
Q4 2022 Feb 13, 2023	SELL	$17.68 - $25.53 $493,590 - $712,746	-27,918 Reduced 16.43%	141,999 $3.38 Million
Q3 2022 Nov 03, 2022	BUY	$17.46 - $26.0 $2.43 Million - $3.62 Million	139,256 Added 454.18%	169,917 $3.35 Million
Q2 2022 Aug 12, 2022	SELL	$14.54 - $27.17 $102,536 - $191,602	-7,052 Reduced 18.7%	30,661 $598,000
Q1 2022 May 16, 2022	BUY	$17.31 - $26.4 $652,812 - $995,623	37,713 New	37,713 $962,000

Others Institutions Holding RVMD

# of Institutions

266

Shares Held

161M

Call Options Held

260K

Put Options Held

620K

View Full List

About Revolution Medicines, Inc.

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $4.95B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

More about RVMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account